Cancer MicroenvironmentPub Date : 2015-12-01Epub Date: 2014-09-07DOI: 10.1007/s12307-014-0152-8
A Rigoni, M P Colombo, C Pucillo
{"title":"The Role of Mast Cells in Molding the Tumor Microenvironment.","authors":"A Rigoni, M P Colombo, C Pucillo","doi":"10.1007/s12307-014-0152-8","DOIUrl":"https://doi.org/10.1007/s12307-014-0152-8","url":null,"abstract":"<p><p>Mast cells (MCs) are granulocytic immune cells that reside in tissues exposed to the external environment. MCs are best known for their activity in allergic reactions, but they have been involved in different physiological and pathological conditions. In particular, MC infiltration has been shown in several types of human tumors and in animal cancer models. Nevertheless, the role of MCs in the tumor microenvironment is still debated because they have been associated either to good or poor prognosis depending on tumor type and tissue localization. This dichotomous role relies on MC capacity to secrete a broad spectrum of molecules with modulatory functions, which may condition the final tumor outcome also promoting angiogenesis and tissue remodeling. In this review, we analyze the multifaceted role of mast cell in tumor progression and inhibition considering their ability to interact with: i) immune cells, ii) tumor cells and iii) the extracellular matrix. Eventually, the current MC targeting strategies to treat cancer patients are discussed. Deciphering the actual role of MCs in tumor onset and progression is crucial to identify MC-targeted treatments aimed at killing cancer cells or at making the tumor vulnerable to selected anti-cancer drugs. </p>","PeriodicalId":9425,"journal":{"name":"Cancer Microenvironment","volume":"8 3","pages":"167-76"},"PeriodicalIF":0.0,"publicationDate":"2015-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s12307-014-0152-8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32645742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer MicroenvironmentPub Date : 2015-12-01Epub Date: 2014-06-04DOI: 10.1007/s12307-014-0147-5
Ronit Vogt Sionov, Zvi G Fridlender, Zvi Granot
{"title":"The Multifaceted Roles Neutrophils Play in the Tumor Microenvironment.","authors":"Ronit Vogt Sionov, Zvi G Fridlender, Zvi Granot","doi":"10.1007/s12307-014-0147-5","DOIUrl":"https://doi.org/10.1007/s12307-014-0147-5","url":null,"abstract":"<p><p>Neutrophils are myeloid cells that constitute 50-70 % of all white blood cells in the human circulation. Traditionally, neutrophils are viewed as the first line of defense against infections and as a major component of the inflammatory process. In addition, accumulating evidence suggest that neutrophils may also play a key role in multiple aspects of cancer biology. The possible involvement of neutrophils in cancer prevention and promotion was already suggested more than half a century ago, however, despite being the major component of the immune system, their contribution has often been overshadowed by other immune components such as lymphocytes and macrophages. Neutrophils seem to have conflicting functions in cancer and can be classified into anti-tumor (N1) and pro-tumor (N2) sub-populations. The aim of this review is to discuss the varying nature of neutrophil function in the cancer microenvironment with a specific emphasis on the mechanisms that regulate neutrophil mobilization, recruitment and activation. </p>","PeriodicalId":9425,"journal":{"name":"Cancer Microenvironment","volume":"8 3","pages":"125-58"},"PeriodicalIF":0.0,"publicationDate":"2015-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s12307-014-0147-5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32396756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"7th International conference on Tumor Microenvironment: Progression, Therapy& Prevention Tel Aviv, Israel October 11 -15, 2015.","authors":"","doi":"10.1007/s12307-015-0175-9","DOIUrl":"https://doi.org/10.1007/s12307-015-0175-9","url":null,"abstract":"","PeriodicalId":9425,"journal":{"name":"Cancer Microenvironment","volume":"8 Suppl 1","pages":"1-141"},"PeriodicalIF":0.0,"publicationDate":"2015-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s12307-015-0175-9","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34008309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer MicroenvironmentPub Date : 2015-08-01Epub Date: 2015-08-14DOI: 10.1007/s12307-015-0172-z
R L Eefsen, L Engelholm, W Alpizar-Alpizar, G G E Van den Eynden, P B Vermeulen, I J Christensen, O D Laerum, H C Rolff, G Høyer-Hansen, B Vainer, K Osterlind, M Illemann
{"title":"Inflammation and uPAR-Expression in Colorectal Liver Metastases in Relation to Growth Pattern and Neo-adjuvant Therapy.","authors":"R L Eefsen, L Engelholm, W Alpizar-Alpizar, G G E Van den Eynden, P B Vermeulen, I J Christensen, O D Laerum, H C Rolff, G Høyer-Hansen, B Vainer, K Osterlind, M Illemann","doi":"10.1007/s12307-015-0172-z","DOIUrl":"https://doi.org/10.1007/s12307-015-0172-z","url":null,"abstract":"<p><p>Proteolytic activity and inflammation in the tumour microenvironment affects cancer progression. In colorectal cancer (CRC) liver metastases it has been observed that three different immune profiles are present, as well as proteolytic activity, determined by the expression of urokinase-type plasminogen activator (uPAR).The main objectives of this study were to investigate uPAR expression and the density of macrophages (CD68) and T cells (CD3) as markers of inflammation in resected CRC liver metastases, where patients were neo-adjuvantly treated with chemotherapy with or without the angiogenesis inhibitor bevacizumab. Chemonaive patients served as a control group. The markers were correlated to growth patterns (GP) of liver metastases, i.e. desmoplastic, pushing and replacement GP. It was hypothesised that differences in proteolysis and inflammation could reflect tumour specific growth and therapy related changes in the tumour microenvironment. In chemonaive patients, a significantly higher level of uPAR was observed in desmoplastic liver metastases in comparison to pushing GP (p = 0.01) or replacement GP (p = 0.03). A significantly higher density of CD68 was observed in liver metastases with replacement GP in comparison to those with pushing GP (p = 0.01). In liver metastases from chemo treated patients, CD68 density was significantly higher in desmoplastic GP in comparison to pushing GP (p = 0.03). In chemo and bevacizumab treated patients only a significant lower CD3 expression was observed in liver metastases with a mixed GP than in those with desmoplastic (p = 0.01) or pushing GP (p = 0.05). Expression of uPAR and the density of macrophages at the tumour margin of liver metastasis differ between GP in the untreated patients. A higher density of T cells was observed in the bevacizumab treated patients, when desmoplastic and pushing metastases were compared to liver metastases with a mix of the GP respectively, however no specific correlations between the immune markers of macrophages and T cells or GP of liver metastases could be demonstrated. </p>","PeriodicalId":9425,"journal":{"name":"Cancer Microenvironment","volume":"8 2","pages":"93-100"},"PeriodicalIF":0.0,"publicationDate":"2015-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s12307-015-0172-z","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33917829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer MicroenvironmentPub Date : 2015-08-01Epub Date: 2015-08-04DOI: 10.1007/s12307-015-0171-0
Sean Curran, Marguerite M Vantangoli, Kim Boekelheide, Jeffrey R Morgan
{"title":"Architecture of Chimeric Spheroids Controls Drug Transport.","authors":"Sean Curran, Marguerite M Vantangoli, Kim Boekelheide, Jeffrey R Morgan","doi":"10.1007/s12307-015-0171-0","DOIUrl":"https://doi.org/10.1007/s12307-015-0171-0","url":null,"abstract":"<p><p>It is well-established that upregulation of drug efflux pumps leads to multi-drug resistance. Less is known about the role of the architecture of the tumor microenvironment in this process: how the location of pump expressing cells influences drug exposure to cancerous as well as non-cancerous cells. Here, we report a 3D in vitro model of spheroids with mixtures of cells expressing high and low levels of ABCG2, quantifying pump activity by the ability to reject the fluorescent dye Hoechst 33342. With respect to the organization of the mixed spheroids, three different architectures were observed: 1) high-expressing ABCG2 cells located in the spheroid core surrounded by low-expressing cells, 2) high-expressing ABCG2 cells intermixed with low-expressing cells and 3) high-expressing ABCG2 cells surrounding a core of low-expressing cells. When high-expressing ABCG2 cells were in the core or intermixed, Hoechst uptake was directly proportional to the percentage of ABCG2 cells. When high-expressing ABCG2 cell formed an outer coating surrounding spheroids, small numbers of ABCG2 cells were disproportionately effective at inhibiting uptake. Specific inhibitors of the ABCG2 transporter eliminated the effect of this coating. Confocal microscopy of spheroids revealed the location of high- and low-expressing cells, and Hoechst fluorescence revealed that the ABCG2-dependant drug concentration in the cancer microenvironment is influenced by pump expression level and distribution among the cells within a tissue. In addition to providing a 3D model for further investigation into multicellular drug resistance, these data show that the location of ABCG2-expressing cells can control drug exposure within the tumor microenvironment. </p>","PeriodicalId":9425,"journal":{"name":"Cancer Microenvironment","volume":"8 2","pages":"101-9"},"PeriodicalIF":0.0,"publicationDate":"2015-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s12307-015-0171-0","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34063345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer MicroenvironmentPub Date : 2015-08-01Epub Date: 2015-06-18DOI: 10.1007/s12307-015-0168-8
Eiji Kiyohara, Nicholas Donovan, Ling Takeshima, Sharon Huang, James S Wilmott, Richard A Scolyer, Peter Jones, Elizabeth B Somers, Daniel J O'Shannessy, Dave S B Hoon
{"title":"Endosialin Expression in Metastatic Melanoma Tumor Microenvironment Vasculature: Potential Therapeutic Implications.","authors":"Eiji Kiyohara, Nicholas Donovan, Ling Takeshima, Sharon Huang, James S Wilmott, Richard A Scolyer, Peter Jones, Elizabeth B Somers, Daniel J O'Shannessy, Dave S B Hoon","doi":"10.1007/s12307-015-0168-8","DOIUrl":"https://doi.org/10.1007/s12307-015-0168-8","url":null,"abstract":"<p><p>Ontuxizumab (MORAb-004) is a humanized recombinant antibody targeting endosialin (TEM-1, CD248). We conducted an analysis of endosialin expression in metastatic melanoma specimens using the anti-endosialin rat anti- MAb 9G5, in order to determine the potential of endosialin as a therapeutic target within the tumor microenvironment vasculature. Endosialin expression in paraffin-embedded archival tissue block (PEAT) melanoma tissues was assessed using immunohistochemistry (IHC) with the anti-endosialin, MAb 9G5, in the vessels of American Joint Commission on Cancer (AJCC) Stage III (n = 18) and Stage IV (n = 48) specimens. IHC for endosialin expression was further performed on a TMA that included 136 Stage IV and 33 paired Stage III melanoma specimens. BRAF mutation (mt) was also evaluated in individual melanoma specimens and as well as the TMA. Analysis showed 70 % of melanoma specimens (n = 46) were positive for endosialin expression. There was no significant difference in endosialin and BRAFmt expression between stages III vs. IV specimens. Endosialin expression was detected in 86 % (n = 117) of stage IV TMA specimens, while no expression was detected in 29 normal tissue controls. MAb 9G5 detects the presence of endosialin in the microenvironment tumor vasculature of most metastatic melanoma tissues, regardless of clinical stage and presence of BRAFmt. Endosialin may be a potential therapeutic target by virtue of its selective expression in metastatic melanoma relative to normal tissues. </p>","PeriodicalId":9425,"journal":{"name":"Cancer Microenvironment","volume":"8 2","pages":"111-8"},"PeriodicalIF":0.0,"publicationDate":"2015-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s12307-015-0168-8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33397852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer MicroenvironmentPub Date : 2015-08-01Epub Date: 2013-11-29DOI: 10.1007/s12307-013-0141-3
Joshua P Landreneau, Michael R Shurin, Marianna V Agassandian, Anton A Keskinov, Yang Ma, Galina V Shurin
{"title":"Immunological Mechanisms of Low and Ultra-Low Dose Cancer Chemotherapy.","authors":"Joshua P Landreneau, Michael R Shurin, Marianna V Agassandian, Anton A Keskinov, Yang Ma, Galina V Shurin","doi":"10.1007/s12307-013-0141-3","DOIUrl":"https://doi.org/10.1007/s12307-013-0141-3","url":null,"abstract":"<p><p>Traditionally, anticancer chemotherapy has been generally considered to be strongly immunosuppressive. However, increasing evidence suggests that certain chemotherapeutic agents rely on the induction of antitumor immune responses, in both experimental animal models and patients with cancer. Many of these chemotherapeutic agents exert immunogenic effects via the induction and release of immunostimulatory \"danger\" signals from dying cancerous cells when used in low doses. New data suggests that several common chemotherapeutic agents may also display direct stimulating effects on immune cells even when applied in ultra-low concentrations (chemoimmunomodulation). Importantly, it is becoming clear that both immune effector cells and immune regulatory cells can be targeted by various chemotherapeutic agents to produce favorable antitumor immune responses. Therefore, utilizing cancer drugs to enhance host antitumor immunity should be considered a feasible therapeutic approach; and recent characterization of the immunomodulatory mechanisms of anticancer chemotherapy using both new and traditional cytotoxic agents suggests that combinations of these approaches with \"classical\" immunomodulatory agents could lead to a viable new therapeutic paradigm for the treatment of cancer. </p>","PeriodicalId":9425,"journal":{"name":"Cancer Microenvironment","volume":"8 2","pages":"57-64"},"PeriodicalIF":0.0,"publicationDate":"2015-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s12307-013-0141-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31917312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer MicroenvironmentPub Date : 2015-08-01Epub Date: 2015-07-04DOI: 10.1007/s12307-015-0169-7
Neha Mehta, Sasikala Muthusamy, Alka Bhatia
{"title":"Do Platelets Inhibit the Effect of Aspirin on Cancer Cells?","authors":"Neha Mehta, Sasikala Muthusamy, Alka Bhatia","doi":"10.1007/s12307-015-0169-7","DOIUrl":"https://doi.org/10.1007/s12307-015-0169-7","url":null,"abstract":"<p><p>Both platelets and cancer cells display an intimate reciprocal crosstalk resulting in alteration of each other's properties. Although many past studies have tried to demonstrate effect of platelets on tumour cells, exact role of platelets in carcinogenesis is still not clear. In the above study, we explored the effect of different concentrations of platelet rich plasma (PRP) on viability, proliferation and adhesion of HeLa cells in culture conditions. The above parameters were found to be slightly increased on incubation with lower two concentrations of PRP (4.4 × 10(5) & 1 × 10(6) platelets/μl) while a reverse effect was seen at high PRP concentration (2 × 10(6) lac platelets/μl) especially at 24 h. To further validate that the above effects were due to platelets we repeated the experiments in the presence of antiplatelet drug aspirin (20 mM). On treatment with aspirin alone, the cell viability, proliferation and adhesion were seen to be decreased indicating cytotoxicity of aspirin towards HeLa cells. However, all of the above parameters were found to increase on addition of all PRP concentrations at 24 h. Overall, variations in the number of platelets produced different effects on the cancer cells. Use of aspirin reduced the viability of the cancer cells, but this effect was seen to be partially reversed by all the concentrations of PRP used. </p>","PeriodicalId":9425,"journal":{"name":"Cancer Microenvironment","volume":"8 2","pages":"119-22"},"PeriodicalIF":0.0,"publicationDate":"2015-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s12307-015-0169-7","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34261597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer MicroenvironmentPub Date : 2015-08-01Epub Date: 2015-08-11DOI: 10.1007/s12307-015-0170-1
Christina Hart, Martin Vogelhuber, Daniel Wolff, Sebastian Klobuch, Lina Ghibelli, Jürgen Foell, Selim Corbacioglu, Klaus Rehe, Guy Haegeman, Simone Thomas, Wolfgang Herr, Albrecht Reichle
{"title":"Anakoinosis: Communicative Reprogramming of Tumor Systems - for Rescuing from Chemorefractory Neoplasia.","authors":"Christina Hart, Martin Vogelhuber, Daniel Wolff, Sebastian Klobuch, Lina Ghibelli, Jürgen Foell, Selim Corbacioglu, Klaus Rehe, Guy Haegeman, Simone Thomas, Wolfgang Herr, Albrecht Reichle","doi":"10.1007/s12307-015-0170-1","DOIUrl":"https://doi.org/10.1007/s12307-015-0170-1","url":null,"abstract":"<p><p>Disruptive technologies, such as communicative reprogramming (anakoinosis) with cellular therapies in situ for treating refractory metastatic cancer allow patient care to accelerate along a totally new trajectory and highlight what may well become the next sea change in the care of patients with many types of advanced neoplasia. Cellular therapy in situ consisted of repurposed drugs, pioglitazone plus all-trans retinoic acid or dexamethasone or interferon-alpha (dual transcriptional modulation) combined with metronomic low-dose chemotherapy or low-dose 5-azacytidine, plus/minus classic targeted therapy. The novel therapeutic tools for specifically designing communication processes within tumor diseases focus on redirecting (1) rationalizations of cancer hallmarks (constitution of single cancer hallmarks), (2) modular events, (3) the 'metabolism' of evolutionary processes (the sum of therapeutically and intrinsically inducible evolutionary processes) and (4) the holistic communicative context, which determines validity and denotation of tumor promoting communication lines. Published data on cellular therapies in situ (6 histologic tumor types, 144 patients, age 0.9-83 years) in castration-resistant prostate cancer, pretreated renal clear cell carcinoma, chemorefractory acute myelocytic leukemia, multiple myeloma > second-line, chemorefractory Hodgkin lymphoma or multivisceral Langerhans cell histiocytosis, outline the possibility for treating refractory metastatic cancer with the hope that this type of reprogrammed communication will be scalable with minimal toxicity. Accessibility to anakoinosis is a tumor inherent feature, and cellular therapy in situ addresses extrinsic and intrinsic drug resistance, by redirecting convergent organized communication tools, while been supported by quite different pattern of (molecular-)genetic aberrations. </p>","PeriodicalId":9425,"journal":{"name":"Cancer Microenvironment","volume":"8 2","pages":"75-92"},"PeriodicalIF":0.0,"publicationDate":"2015-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s12307-015-0170-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33910513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer MicroenvironmentPub Date : 2015-08-01Epub Date: 2015-05-16DOI: 10.1007/s12307-015-0167-9
Malyn May Asuncion Valenzuela, Heather R Ferguson Bennit, Amber Gonda, Carlos J Diaz Osterman, Abby Hibma, Salma Khan, Nathan R Wall
{"title":"Exosomes Secreted from Human Cancer Cell Lines Contain Inhibitors of Apoptosis (IAP).","authors":"Malyn May Asuncion Valenzuela, Heather R Ferguson Bennit, Amber Gonda, Carlos J Diaz Osterman, Abby Hibma, Salma Khan, Nathan R Wall","doi":"10.1007/s12307-015-0167-9","DOIUrl":"https://doi.org/10.1007/s12307-015-0167-9","url":null,"abstract":"<p><p>Exosomes are endosomal-derived nanovesicles released by normal and tumor cells which have been shown to transfer functionally active protein, lipids, mRNAs and miRNAs between cells. Varying in molecular profiles, biological roles, functional roles and protein contents, exosomes have been described as \"multi-purpose carriers\" playing a role in supporting the survival and growth of tumor cells. The IAP Survivin has been found to be present in tumor exosomes. However, the existence of other IAPs in tumor exosomes is still unknown. Survivin, cIAP1, cIAP2 and XIAP mRNA and protein are differently expressed in a panel of tumor cell lines: DLCL2, HeLa, MCF-7, Panc-1, and PC3. Exosomes were isolated from conditioned media collected from the cells from which RNA and protein were extracted. Our results provide evidence that like Survivin, XIAP, cIAP1 and cIAP2 proteins are found in tumor exosomes. The mRNA expression, however, is differentially expressed across the tumor cell lines. The presence of these bioactive molecules in exosomes may not only serve as warning signals, but also play a role in providing protection to the cancer cells against changes that are constantly occurring in the tumor microenvironment. </p>","PeriodicalId":9425,"journal":{"name":"Cancer Microenvironment","volume":"8 2","pages":"65-73"},"PeriodicalIF":0.0,"publicationDate":"2015-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s12307-015-0167-9","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33310328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}